NKTR been quietly moving up. As it seems the consensus is that a decision should be made on NKTR-181 late summer early fall, this may be the start of a run into that event. Maybe, maybe not. In any event I added a call option to lower the cost on my common starter position. The call is out to Jan 2019 to be able to cover the next news event on NKTR’s cancer drug due in November. I’m willing to lose the cost of the call.
Rob
NKTR been quietly moving up. As it seems the consensus is that a decision should be made on NKTR-181 late summer early fall, this may be the start of a run into that event. Maybe, maybe not. In any event I added a call option to lower the cost on my common starter position. The call is out to Jan 2019 to be able to cover the next news event on NKTR’s cancer drug due in November. I’m willing to lose the cost of the call.
Rob
I noticed the creep upward too. I have some January 2020 leap calls. I am also willing to lose the cost of the calls - the upside with any positive news in the interim is quite large.
No later than yesterday Saul wrote
“NOT ON THIS BOARD! Options discussions are Off-Topic and not welcome on the board.”
No later than yesterday Saul wrote
“NOT ON THIS BOARD! Options discussions are Off-Topic and not welcome on the board.”
Good point, sorry. On the other hand, NKTR has been a major topic of interest here and the manner of investment was secondary but relevant to the original post.
No later than yesterday Saul wrote
“NOT ON THIS BOARD! Options discussions are Off-Topic and not welcome on the board.”
I also would like to add that yes, we should honor Saul’s wishes and avoid the subject completely.